Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets

J Virol. 2004 Nov;78(22):12672-6. doi: 10.1128/JVI.78.22.12672-12676.2004.

Abstract

Severe acute respiratory syndrome (SARS) caused by a newly identified coronavirus (SARS-CoV) is a serious emerging human infectious disease. In this report, we immunized ferrets (Mustela putorius furo) with recombinant modified vaccinia virus Ankara (rMVA) expressing the SARS-CoV spike (S) protein. Immunized ferrets developed a more rapid and vigorous neutralizing antibody response than control animals after challenge with SARS-CoV; however, they also exhibited strong inflammatory responses in liver tissue. Inflammation in control animals exposed to SARS-CoV was relatively mild. Thus, our data suggest that vaccination with rMVA expressing SARS-CoV S protein is associated with enhanced hepatitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral / blood
  • Ferrets
  • Hepatitis / etiology*
  • Liver / pathology
  • Male
  • Membrane Glycoproteins / genetics
  • Membrane Glycoproteins / immunology*
  • Reverse Transcriptase Polymerase Chain Reaction
  • SARS Virus / immunology*
  • Spike Glycoprotein, Coronavirus
  • Vaccination
  • Vaccines, Synthetic / adverse effects*
  • Vaccinia virus / immunology*
  • Viral Envelope Proteins / genetics
  • Viral Envelope Proteins / immunology*
  • Viral Vaccines / adverse effects*

Substances

  • Antibodies, Viral
  • MHV surface projection glycoprotein
  • Membrane Glycoproteins
  • Spike Glycoprotein, Coronavirus
  • Vaccines, Synthetic
  • Viral Envelope Proteins
  • Viral Vaccines
  • spike glycoprotein, SARS-CoV